Organic Active Ingredients TRIZ Cases

Using trichostatin A as a single dual HDAC-AURKA inhibitor simplifies cancer treatment while suppressing AURKA expression.

Substituted pyrrolopyridines inhibit TLR9 while preserving TLR7 and TLR8 selectivity, supporting fibrosis treatment with drug-like stability.

Novel tricyclic heteroaryl compounds inhibit CDK and TRK kinases to address resistance and suppress abnormal tumor cell growth.

Crystalline salt forms tune plasma kallikrein inhibitor stability and pharmacokinetics for oral therapy while reducing reocclusion and bleeding risk.

Low-temperature hydrolysis at 10°C or below limits conjugated fatty acids and color formation while producing high-purity free polyunsaturated fatty acids.

A multi-target neuroprotective compound is tuned to cross the blood-brain barrier while resisting excitotoxicity and limiting cardiotoxicity.

Blocking PTGDR-1 and PTGDR-2 limits basophil homing, autoantibody production, and kidney inflammation in systemic lupus erythematosus.

A permeation-enhanced transdermal CBD gel treats SYNGAP1 seizures and behavioral symptoms while avoiding GI effects and somnolence.

Novel bipyridinone GPR139 antagonists improve therapeutic efficacy across CNS disorders by modulating neural activity in the habenular nucleus.

A controlled oral minoxidil formulation balances faster onset with steadier pharmacokinetic levels to limit adverse effects in hair loss treatment.

Dual-site CK2α prodrugs improve kinase selectivity and solubility by combining ATP-site binding with αD-site interaction.

Targeting ACSS2 blocks acetate-to-acetyl-CoA metabolism in hypoxic cancer cells, reducing lipid and histone synthesis while limiting normal-cell impact.

Antisense oligomers induce Scarb1 exon 12 skipping to rebalance SR-BI/SR-BII, reducing liver lipids and inflammation in MAFLD.

PEGylated menaquinol derivatives extend vitamin K bioavailability and serum half-life to improve bone mineralization and reduce vascular calcification.

Polyester nanoparticles and hyaluronan stabilize topical oil-in-water emulsions without surfactants, reducing irritation while improving skin delivery.

Adsorbing low-dose corticosteroid onto silicified microcrystalline cellulose improves ODT uniformity and topical esophageal treatment.

A two-layer biodegradable implant releases chemotherapy toward target tissue while blocking systemic leakage and avoiding removal surgery.

Benzofuran derivatives inhibit SIK1-3 to lower pro-inflammatory cytokines and boost IL-10 secretion for inflammatory disease treatment.

Salt and cocrystal forms improve psilocin solubility and aqueous stability, enabling more predictable dosing and injectable use.

Deprotonated cannabinoids form stable aqueous solutions, overcoming poor water solubility to improve beverage formulation and bioavailability.

Indoline derivatives directly bind 5-HT2A receptors to preserve serotonergic therapy while reducing hallucinogenic side effects.

Sialic acid compositions raise mucosal sialic acid levels to compete for SARS-CoV-2 binding and reduce epithelial infection risk.

Using low-hydrolysis PVA and a three-fluid nozzle, this case solves solvent incompatibility to stabilize amorphous APIs and improve dissolution.

Cyclic sulfonamide RNR inhibitors improve selective RNR binding, induce replication stress, and reduce tumor growth with fewer off-target effects.

Cleavable benzodiazepine ADC linkers stay stable in circulation, then release cytotoxic agents in cancer cells to limit harm to healthy tissues.

Combining L-rhamnose with EPA and DHA enables large-intestine release that raises propionate and improves the propionate-to-acetate ratio.

Using alpha-lipoic acid trisulfide derivatives, this case shows how antioxidant and anti-inflammatory action helps prevent or alleviate hepatic dysfunction.

By silencing angiotensinogen mRNA upstream of RAAS, these nucleic acids help avoid compensatory escape seen with conventional hypertension drugs.

Microbially fermented carbohydrate biopolymers improve ocular water retention and shear-thinning, extending dry eye relief without animal-derived HA.

A neuraminidase inhibitor promotes neuron migration to brain injury sites, offering a less invasive alternative to cell transplantation.

Self-assembled RNA complexes use cholesterol-linked siRNA and sense-strand digestion to overcome endosomal trapping and inhibit metastasis.

A heat-treated PVA implant enables near-constant intraocular nintedanib release for months while avoiding polymer biodegradation issues.

Intracisternal rAAV delivery uses CSF flow to bypass the blood-brain barrier and spread therapeutic proteins across the CNS.

Separating cell-free and surface-bound nucleic acids enables mutation mapping that localizes tissue sources in mixed blood signals.

Blood platelets carry KRASG12D-targeting siRNA to tumors, improving delivery persistence while reducing systemic toxicity.

Milk lactose is enzymatically converted into high in situ GOS, avoiding added calories and labeling while delivering fiber-rich dairy products.

Buffer, sugar, and surfactant excipients stabilize ADC injections during storage, limiting aggregation and degradation to preserve efficacy.

Glucuronide and sulfate catecholamine prodrugs improve oral bioavailability and sustain plasma exposure to reduce dyskinesia and off fluctuations.

By mixing nicotine and acid vapors into a nicotine salt aerosol, this case improves absorption speed while reducing irritation.

Novel compounds selectively modulate SMARCA and PB1 proteins to improve cancer therapy while limiting non-specific effects.

A core-shell opioid dosage form uses separate matrix layers to resist crushing and solvent extraction while maintaining near zero-order release over 8-24 hours.

Mazindol combines NRI, SRI, DRI, and μ-opioid agonist activity to treat CNS disorders with broader efficacy and fewer side effects.

A β-helical protein conjugate carries gene-editing cargo across cell membranes without endocytosis, reducing degradation and improving delivery.

A nasal apigenin, BBB-traversing peptide, and porosome composition aims to restore neuronal secretion and slow early Alzheimer's progression.

AMHR2-targeted vaccine compositions boost durable anti-tumor immunity to inhibit ovarian cancer growth and recurrence with minimal autoimmune risk.

Squaramide CB1 allosteric modulators improve pharmacokinetics and therapeutic efficacy for obesity and substance abuse while reducing adverse effects.

Novel crystalline forms are selected and characterized by XRPD and thermal analysis to improve solubility, stability, and formulation reliability.

Measuring HTI vaccine T-cell response helps identify when HIV patients may continue, stop, or avoid prolonged ART while maintaining control.

A fixed-dose bictegravir and lenacapavir tablet cuts pill burden while maintaining pharmacokinetic performance and HIV treatment adherence.

Formula I antiviral prodrugs bypass metabolic barriers to strengthen viral polymerase inhibition against West Nile and Zika with lower cytotoxicity.

Bicyclic urea compounds selectively inhibit the JAK2 V617F mutant while preserving essential JAK2 signaling needed for normal function.

By shifting cells from fatty acid to glucose oxidation, linked trimetazidine and NAD+ precursors improve rheumatic treatment while limiting side effects.

Nasal apigenin with cyclic peptides targets mitochondrial fission in brain cells, improving viability and reducing oxidative stress.

Senolytic agents clear senescent bone marrow stromal cells to curb clonal hematopoiesis, reduce myeloproliferation, and delay AML.

Novel posiphen D-tartrate crystal forms balance solubility and stability, with Form B enabling faster delivery and longer retention.

Novel crystalline oxazolidinone forms improve stability and processing, enabling lower-cost manufacturing for tuberculosis treatment.

Ganoderma-derived β-1,3/1,6-D-glucan targets inflammation and oxidative stress in STEMI and digestive disorders through immune modulation.

Mannitol starter cores enable talc-free fluidized bed coating, reducing agglomeration, sedimentation, and nozzle clogging at industrial scale.

Genipin crosslinking helps thermally shrunk collagen tissue retain strength and resist stretch-back for more durable laxity treatment.

DLL3-targeting antibodies and CAR T cells improve selective killing of neuroendocrine cancer cells while limiting off-tumor effects.

A selective irreversible BTK inhibitor enables single-dose immune disease treatment with sustained efficacy, better safety, and improved compliance.

Controlled phosphorothioate stereochemistry and conjugated moieties help APOC3 oligonucleotides resist nucleases while preserving RNAi activity.

Low-molecular-weight mucoadhesive polymers crosslink mucus without aggregation, reinforcing the barrier against sperm and microorganisms.

Allosteric pyrroloquinazoline-ketone compounds selectively inhibit galectin-3 to reduce side effects in inflammation, fibrosis, and cancer.

Hydroxytryptophan-based excipients reduce protein oxidation during formulation and storage while preserving stability and biological activity.

ER stress-reducing agents help repair sleep deprivation-induced gut damage, easing nutrient malabsorption and cellular injury.

Cleavable branched PEG linkers and fully human anti-CD19 antibodies improve ADC stability and limit premature payload release.

Adjusted bupropion and dextromethorphan dosing lowers somnolence and dizziness in renal impairment while accounting for CYP2D6 interactions.

EpCAM-targeted anti-FAP siRNA conjugates improve ovarian cancer cell uptake and suppress FAP-driven tumor growth and relapse.

Oral nystatin targets persistent intestinal SARS-CoV-2 by disrupting the viral envelope, reducing gut viral burden and post-COVID symptoms.

Localized nasal delivery of isolithocholic acid suppresses neutrophil influx and cytokine release while reducing off-target risks in lung inflammation.

A Lactobacillus strain paired with vitamin D3 boosts serum absorption quickly, even with sterol absorption issues, without raising cholesterol.

A Formula I compound selectively inhibits IRAK4 to curb proinflammatory cytokines while maintaining kinase selectivity and suitable pharmacokinetics.

Defined PTK7-binding CDR sequences enable ADCs with better stability, longer half-life, and a wider therapeutic window in cancer treatment.

Selective imidazopyridine and imidazopyrazine compounds improve α2/3-GABAA receptor affinity and modulation while aiming to limit side effects.

A GST fusion protein forms a nanoparticle corona that improves target-cell binding while reducing immune clearance and extending in vivo retention.

Long-chain fatty acid triglycerides mask butyrate odor and taste while reducing gastric lipolysis for effective intestinal delivery.

A novel anti-LRRC15 antibody binds epitopes in residues 22-315 and enables a PBD-linked ADC with strong antitumor activity.

A new oxo-pyrido CGRP antagonist structure improves migraine relief while lowering cardiovascular risk, adverse reactions, and PK instability.

Timed and titrated beinaglutide dosing offsets rapid DPP4 degradation, lowering HbA1c and body weight while limiting side effects.

Formula (I) neuroactive steroids modulate GABA A receptors to control chloride ion flow and brain excitability for CNS disorder treatment.

Using kaempferol saccharides from Camellia seed cake, this case shows wrinkle improvement and skin regeneration with lower side-effect risk.

Blocking Gardos channel and erythrocyte adhesion pathways helps prevent red blood cell dehydration, reduce breakdown, and sustain haemoglobin.

Covalently coupled CpG ODNs guide B cells to diseased lymphoid organs and inhibit pathogenic activation while preserving humoral immunity.

Novel diazabicyclic sulfonylamidine inhibitors block multiple β-lactamase classes and restore β-lactam antibiotic activity against resistant bacteria.

Dual inhibition of c-KIT and MEK/ERK pathways helps overcome secondary mutation resistance in GIST and drives apoptosis and tumor regression.

A hydrophilic linker enables stable antibody conjugation of amino-containing drugs like exatecan while reducing hydrophobicity and improving pharmacokinetics.

Advisory-based E7766 dosing and timing guidance helps prevent OATP inhibitor interactions, overexposure, and adverse effects.